FAPI成像:突破传统PET/CT在癌症诊断中的局限性  

FAPI imaging:breaking the limitations of traditional PET/CT in cancer diagnosis

作　　者：董欣 孙瑶[1] 汪菲 张术 谢国柱[1] DONG Xin;SUN Yao;WANG Fei;ZHANG Shu;XIE Guozhu(Department of Radiation Therapy,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China)

机构地区：[1]南方医科大学南方医院放疗科,广东广州510515

出　　处：《分子影像学杂志》2024年第5期542-547,共6页Journal of Molecular Imaging

基　　金：国家自然科学基金(82373302);广州市科技计划“领航”项目(2024A04J6613)

摘　　要：近年来,传统的^(18)F-氟代脱氧葡萄糖PET/CT在癌症诊断中得到广泛应用,但其在检测微小转移和淋巴结转移及显像特异性方面存在一定局限性。成纤维细胞激活蛋白α(FAPα)是肿瘤微环境中肿瘤相关成纤维细胞的特征性分子标记之一,其在90%的恶性实体瘤中呈现出高表达模式。靶向FAPα的新型放射性显像剂-^(68)Ga标记的成纤维细胞激活蛋白抑制剂(^(68)Ga-FAPI),已在多种肿瘤中显示出突破性的诊断潜力。本文综述了FAPI成像技术的分子基础及发展历程,并回顾了FAPI成像在乳腺癌、肺癌和胰腺癌等多种癌症中的临床应用现状,展示了其在诊断效能上相对于传统^(18)F-FDG的优势,最后讨论了FAPI显像在当前临床推广时面临的主要挑战,旨在突显FAPI成像在癌症诊断中的巨大潜力及其未来的研究方向,以推动该技术的进一步完善和在临床实践中的广泛应用。In recent years,traditional ^(18)F-FDG PET/CT has been widely used in cancer diagnosis.However,it has certain limitations in detecting small metastases and lymph node metastases,as well as imaging specificity.Fibroblast activation proteinα(FAPα)is overexpressed on cancer-associated fibroblasts in approximately 90%of malignant solid tumors.^(68)Ga-labelled radiopharmaceuticals-FAP-inhibitors(FAPI)-have been developed for PET by targeting FAPα,and showed breakthrough diagnostic potential in various tumors.This article reviews the molecular basis and development history of FAPI imaging technology,and reviews the current clinical application status of FAPI imaging in various cancers such as breast cancer,lung cancer,and pancreatic cancer,showing its diagnostic efficacy compared to traditional ^(18)F-FDG.Finally,it discusses the main challenges FAPI imaging faces in current clinical promotion,aiming to highlight the great potential of FAPI imaging in cancer diagnosis and its future research directions,to promote further improvement of the technology and its widespread application in clinical practice.

关 键 词：FAPI PET-CT 放射性显像剂 癌症诊断 

分 类 号：R730.44[医药卫生—肿瘤]